Oruka Therapeutics is focused on improving the experiences of people living with plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications. Self-described as committed to advancing potentially best-in-class monoclonal antibodies for treatment.

Oruka Therapeutics

Oruka Therapeutics | 2,597 followers on LinkedIn. A new era for chronic skin diseases | Advancing novel biologics that aim to offer the greatest possible freedom from disease to people with plaque psoriasis and other associated conditions

Biopharmaceutical Quality Operations Management

Katherine Guise, CQA

VP, Medical Affairs at Oruka Therapeutics

Eugenia Levi

Sr. Director, Clinical Data Management

Evelyn Dorsey

Vice President Regulatory Affairs at Oruka Therapeutics

Jodi Parsons

October 29 is #WorldPsoriasisDay . This year’s theme of “Family” highlights the impact of psoriatic disease on over 100 million people worldwide as well as their loved ones. Psoriasis presents unique challenges not only for those affected but also for their families. At Oruka, we’re dedicated to developing new treatments that aim to ease this burden by offering those living with psoriasis the greatest possible freedom from disease.

We recently celebrated our public listing at the Nasdaq MarketSite in Times Square! We’re proud to mark this achievement along our path to develop novel biologics for plaque psoriasis and related conditions. Photography courtesy of Nasdaq, Inc.

We’re excited to present new preclinical data on ORKA-001, a novel extended half-life monoclonal antibody targeting IL-23p19, at the EADV Congress in Amsterdam. The data show that ORKA-001 has a three-fold longer half-life in non-human primates than risankizumab, while binding to a similar epitope with similar affinity. These findings give us additional confidence that ORKA-001 can achieve our base-case expectation of dosing once every six months and further reason to believe we could reach once-yearly dosing with the potential for higher efficacy, all with the goal of offering people with psoriasis the most possible freedom from their disease.

We’re excited to begin trading on Nasdaq as “ORKA” today following the close of our merger. This transaction and concurrent $275 million financing propel us towards our goal of offering the greatest possible freedom from disease to patients with psoriasis and other associated diseases.

Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

DNSSEC

Content Delivery Network

Font Awesome

Samarth Kulkarni

Health Care Companies With Fewer Than 50 Employees (Top 10K)

United States Medical Public Companies

United States Companies (Top 10K)

Companies That Exited in 2024 (Top 10K)

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

Post-IPO Equity - Oruka Therapeutics

Waltham

Massachusetts

United States

North America

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics GAAP EPS of -$1.46 misses by $1.08 (NASDAQ:ORKA)

Preliminary option volume of 56.7M today

Oruka Therapeutics reports Q3 EPS ($1.46), consensus (40c)

Oruka Therapeutics to Present at Multiple November Investor Conferences

Oruka Therapeutics Announces $200 Million Private Placement

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

A monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23p19) for the treatment of psoriasis and other inflammatory diseases.

A monoclonal antibody targeting interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of psoriasis and other inflammatory diseases.

A pipeline program in the discovery phase aimed at treating psoriasis, psoriatic arthritis, and other related conditions.

India

Asia

Spain

Europe

Pakistan

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 16, 2024 1:52 PM	c477e653
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 16, 2024 1:52 PM	13a1966f
crunchbase trigger	general	Nov 16, 2024 1:52 PM	487fac95
crunchbase profile	general	Nov 16, 2024 2:07 PM	80a53f94
li profile	general	Nov 16, 2024 1:52 PM	ceeeab45
translate crunchbase fundingrounds	general	Nov 16, 2024 2:27 PM	e130b12d
peers	general	Nov 16, 2024 1:52 PM	9097f029
news basic	general	Nov 16, 2024 1:52 PM	281eb9fc
bundesanzeiger	filings
financials download nd	financials
private financials	financials

ORUK

COM:ORUKATX

Oruka Therapeutics